Today, Oxbow Advisors LLC Buys 54,185 Shares of Gilead Sciences Inc. (GILD)

Today, Oxbow Advisors LLC Buys 54,185  Shares of Gilead Sciences Inc. (GILD)
Oxbow Advisors LLC acquired a new stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 54,185 shares of the biopharmaceutical company’s stock, valued at approximately $4,286,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Van Hulzen Asset Management LLC raised its stake in shares of Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 100 shares in the last quarter. Gemmer Asset Management LLC raised its stake in shares of Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 175 shares in the last quarter. Joel Isaacson & Co. LLC raised its stake in shares of Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 226 shares in the last quarter. Roble Belko & Company Inc raised its stake in shares of Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,035 shares in the last quarter. Finally, Pinkerton Retirement Specialists LLC raised its stake in shares of Gilead Sciences by 9,305.9% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,599 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 1,582 shares in the last quarter. 76.65% of the stock is currently owned by institutional investors and hedge funds.

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded up 0.19% during trading on Friday, reaching $75.44. 3,068,606 shares of the company traded hands. The company has a market capitalization of $99.39 billion, a price-to-earnings ratio of 6.98 and a beta of 1.25. The firm’s 50 day moving average price is $74.56 and its 200-day moving average price is $80.20. Gilead Sciences Inc. has a 52 week low of $71.39 and a 52 week high of $108.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing analysts’ consensus estimates of $2.87 by $0.12. The business had revenue of $7.40 billion for the quarter, compared to analyst estimates of $7.47 billion. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The business’s revenue was down 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.22 earnings per share. Equities analysts anticipate that Gilead Sciences Inc. will post $11.47 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 29th. Investors of record on Thursday, December 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $1.88 dividend on an annualized basis and a yield of 2.49%. Gilead Sciences’s payout ratio is presently 17.44%.

A number of equities research analysts have weighed in on GILD shares. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Monday, October 3rd. Jefferies Group decreased their target price on shares of Gilead Sciences from $93.00 to $91.00 and set a “hold” rating for the company in a research note on Wednesday, August 31st. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Monday, September 26th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $108.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 31st. Finally, Leerink Swann set a $112.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, September 22nd. Ten equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $97.90.

In related news, insider John F. Milligan sold 70,000 shares of the business’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $77.74, for a total transaction of $5,441,800.00. Following the transaction, the insider now directly owns 1,128,963 shares in the company, valued at $87,765,583.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John W. Madigan sold 105,000 shares of the business’s stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the transaction, the director now owns 121,761 shares in the company, valued at $9,115,028.46. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Related posts

Leave a Comment